Catalog Number : 500-P01
Produced from sera of rabbits pre-immunized with highly pure (>98%) recombinant hIL-11. Anti-Human IL-11 specific antibody was purified by affinity chromatography employing immobilized hIL-11 matrix.
|Application:||ELISA, Western Blot, Neutralization, Immunohistochemistry|
Anti-Human IL-11 (BioGems Catalog #200-11)
This antibody stained human brain stroke (including control cortex and stroke core areas) tissue. The primary antibody was incubated at 2.5 mg/ml overnight at 4˚C. This was followed by a fluorophore conjugated secondary antibody. Optimal concentrations and conditions may vary.
Information and photo are courtesy of the Tissue Profiling group, SciLifeLab Stockholm.
To yield one-half maximal inhibition [ND50] of the biological activity of hIL-11 (1.50 ng/ml), a concentration of 0.02-0.05 µg/ml of this antibody is required.
To detect hIL-11 by sandwich ELISA (using 100 μl/well antibody solution) a concentration of 0.5 - 2.0 μg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with BioGems' Biotinylated Anti-Human IL-11 (60-011BT) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hIL-11.
To detect hIL-11 by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hIL-11 is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.